XRCC3 and ovarian cancer: No statistically significant associations between XRCC3 rs861539 polymorphisms and ovarian cancer risk were observed in any genetic models (T2T2 versus T1T1: OR = 0.95, 95% CI = 0.85–1.06, P = 0.37; T1T2 versus T1T1: OR = 0.95, 95% CI = 0.88–1.03, P = 0.22; T1T2+T2T2 versus T1T1: OR = 0.95, 95% CI = 0.88–1.02, P = 0.19; T2T2 versus T1T1+T1T2: OR = 0.97, 95% CI = 0.88–1.08, P = 0.63).